Drug Database
ME

measles vaccine (live-attenuated)

✓ Approved

Beijing Tiantan Biological Products · Vaccine · Vaccine

What is measles vaccine (live-attenuated)?

measles vaccine (live-attenuated) is a vaccine developed by Beijing Tiantan Biological Products. It is approved for therapeutic indications via unknown.

Drug Profile

CompanyBeijing Tiantan Biological Products
Drug ClassVaccine, Large Molecules
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, Beijing Tiantan Biological Products

Therapeutic Indications

measles vaccine (live-attenuated) is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeasles✓ Approved

Related Research Articles

PubMedBiomedical and environmental sciences : BES2026-11-12

Estimating Risk of Measles Virus Transmission in Countries with Measles Elimination Status: A Comparative Measles Seroprevalence Study.

Gong Lin Lin LL, Abudurusuli Guzainuer G, Zheng Fan F, Xie Jia Yuan JY et al.

Measles elimination is threatened by the virus's high infectivity (R 0 = 12-18), waning immunity, and persistent immunity gaps. No global study has compared measles seroprevalence before and after elimination. We assessed whether countries that had eliminated measles achieved and maintained the herd immunity threshold and identified key vulnerabilities. For countries with World Health Organization (WHO)-confirmed measles elimination, we systematically searched PubMed, Web of Science, and Google Scholar for seroprevalence data covering the three years before and the three years after elimination verification. Sample-size-weighted medians and interquartile ranges were calculated to describe seroprevalence, with stratified analyses by age group and country. The overall seroprevalence in the three years before and after elimination verification was also compared. Among 31 countries with measles elimination status (351 datasets comprising 562,772 participants), the overall median seroprevalence was 92.8%. Seroprevalence increased significantly with age ( P < 0.001), from 56.5% among infants (aged 0-1 years) to 96.8% among older adults (aged > 40 years). Twenty-six percent of the countries had a seroprevalence of ≥ 92%, indicating a low risk of measles transmission, whereas 45% had a seroprevalence of < 85%, indicating a substantial transmission risk. The median seroprevalence decreased significantly from 94.9% during the three years before elimination verification to 83.5% during the three years after verification ( P < 0.001). Achieving measles elimination does not guarantee that population-level protection will be sustained. Despite high overall seroprevalence, important immunity gaps persist among infants and young children, and some countries do not maintain the required herd immunity threshold following elimination. Targeted interventions are needed to close immunity gaps and strengthen national population immunity to prevent measles resurgence.

PMID 43016183
Read full article →
PubMedJournal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada2026-11-12

When revaccination is recommended: An evaluation of non-guideline poliovirus serology testing in Alberta, Canada.

Rosen Charlotte C, Zelyas Nathan N, Berenger Byron M BM, Zhou Hong Yuan HY et al.

The National Advisory Committee on Immunization (NACI) advises against routine poliovirus serology (POLV-S) testing for poliovirus (POLV) immunity, recommending age-appropriate revaccination when immunity is unknown. POLV-S tests strain laboratory resources, result in unnecessary phlebotomy, and are frequently cancelled due to no primary indication. This study assessed more than one year of provincial POLV-S requests to identify gaps in adherence to national guidelines. Data on POLV-S requests from May 1, 2023, to December 31, 2024, were obtained from the laboratory information system. Patient demographics, physician specialty, years of experience, patient history, indication(s) for testing, availability of vaccine records, and additional serologies ordered were analyzed. Of 108 POLV-S requests (requested by 77 physicians), the median patient age was 34.5 years. All ordering physicians were general practitioners. Three (2.8%) requests were for POLV-S alone; 105 (97.2%) included a median of 7 additional serology tests, most commonly measles, rubella, and mumps IgG (89.8%-90.7%). Patient history was absent in 86 (79.6%) requests. Testing was primarily for employment (45.5%), occupational health forms (27.3%), immigration (13.6%), and immunity verification (13.6%). Vaccine records were available for 50 (46.3%) patients; of these, 56% lacked documentation of a POLV vaccine date. Our findings highlight the need to ensure adherence to NACI guidelines to reduce unnecessary POLV-S testing. Education surrounding the lack of availability of POLV-S testing and the safety and efficacy of revaccination in patients with unknown immunization history will improve laboratory efficiency and ensure immunity to POLV.

PMID 43017667
Read full article →
PubMedAIDS reviews2026-11-12

Herpes zoster vaccination in people living with HIV: from evidence to implementation - A narrative review.

Van Nguyen Hung H, Thi Diem Le Trinh T

Herpes zoster (HZ) remains a significant, preventable cause of morbidity among people living with HIV (PLWH), who face increased risks of HZ, recurrence, and complications despite effective antiretroviral therapy. The recombinant zoster vaccine (RZV), a non-live, adjuvanted vaccine, is currently the preferred strategy for HZ prevention in immunocompromised adults. This narrative review synthesizes the evidence on the burden and pathogenesis of HZ in PLWH, RZV immunogenicity and safety, present vaccination recommendations, clinical considerations, and implementation challenges, with particular emphasis on the Asia-Pacific region. Available evidence indicates that RZV induces robust humoral and cellular immune responses and has a favorable safety profile in PLWH; however, HIV-specific evidence regarding clinical effectiveness, long-term durability of protection, and optimal timing of vaccination in the setting of advanced immunosuppression remains limited. International guidelines consistently recommend a two-dose RZV series for adults with HIV, without requiring a specific CD4+ T-cell threshold or virological suppression. Nevertheless, vaccine uptake remains constrained by cost, limited availability, inadequate patient and healthcare-provider awareness, vaccine hesitancy, and fragmented vaccination services. Future research should prioritize real-world effectiveness, durability of protection, cost-effectiveness, and determinants of vaccine acceptance, including behavioral factors, such as perceived susceptibility, perceived benefits, and perceived barriers. Integrating RZV into routine HIV care and strengthening implementation strategies, particularly across the Asia-Pacific region and other resourcelimited settings, will be critical to translating guideline recommendations into equitable vaccination coverage and reducing HZ-related morbidity among PLWH.

PMID 43018275
Read full article →
PubMedMicrobiology spectrum2026-11-12

m6A coordinates mumps virus replication and innate immune sensing.

Wang Shixuan S, Zhang Yifei Y, Hu Qing Q, Ping Tongyu T et al.

In this study, we test the hypothesis that N6-methyladenosine (m6A) coordinates a functional trade-off between viral replication and innate immune sensing during mumps virus (MuV) infection. Using single-base resolution GLORI-seq, we identified widespread and non-canonically distributed m6A sites across MuV genomic, antigenomic, and messenger RNAs. Functional analyses revealed that depletion of the m6A methyltransferase METTL3 enhances viral RNA synthesis and nucleocapsid encapsidation in interferon-deficient cells, indicating an intrinsic suppressive role of m6A in viral replication. In contrast, in immune-competent epithelial and dendritic cells, host m6A enhances antiviral signaling, as METTL3 deficiency reduces infection-induced interferon and cytokine responses. Mechanistically, m6A-deficient MuV RNA exhibited increased binding to multiple pattern recognition receptors, including RIG-I-like and toll-like receptors, resulting in enhanced innate immune activation. Additionally, MuV infection extensively remodels the host m6A epitranscriptome in a cell type-dependent manner, with m6A enrichment positively correlating with the expression of immune-related transcripts. Together, these findings demonstrate that m6A acts as a bidirectional regulator during MuV infection by simultaneously restricting viral replication and modulating host immune recognition, providing new insight into epitranscriptomic control of paramyxovirus-host interactions.IMPORTANCEN6-methyladenosine (m6A) modification has emerged as a key regulator of RNA virus infection, yet its role in mumps virus (MuV) remains undefined. Here, we map the single-base resolution m6A landscape of a recombinant MuV and demonstrate that viral m6A restricts genome encapsidation and replication while attenuating innate immune sensing. MuV infection extensively remodels host m6A profiles in epithelial and dendritic cells, preferentially enhancing methylation of innate immune transcripts. Strikingly, m6A-deficient MuV RNA exhibits increased affinity for RIG-I-like and toll-like receptors, eliciting stronger interferon and proinflammatory responses. Our findings identify m6A as a bidirectional regulator of MuV replication and immunity and suggest an epitranscriptomic strategy to optimize live-attenuated vaccine design.

PMID 43018140
Read full article →
PubMedBMC public health2026-11-12

Evaluating parents' perceptions of infectious diseases and their levels of protection in terms of vaccination attitudes and vaccine hesitancy.

Gökçay Gönül G, Küçük Hulya Incirkuş HI, Sezer Nazlı Akar NA, Aydin Cansu Mine CM et al.

This research was conducted to evaluate parents' perceptions of infectious diseases and their levels of protection in terms of vaccination attitudes and vaccine hesitancy. The research is descriptive and relational was conducted online with 560 parents of children aged 0-5 years between March 8 and November 8, 2024. Convenience sampling method was used in the study. For data collection, a questionnaire form including personal information form, Perception Scale on Communicable Diseases (PSCD), Parental Attitudes Towards Childhood Vaccines Scale (PACVS), and Vaccine Hesitancy Scale (VHS) in parents of children under five years of age was used. The evaluation of data was performed via SPSS V-27.0 package program. A total of 560 parents took part in this study, and the participants scored an average of 148.81 ± 18.53 points on the PSCD total, 53.42 ± 8.91 points on the Vaccine Attitude Scale total, and 24.89 ± 8.49 points on the Vaccine Hesitancy Scale total. PSCD explains 13.4% of the total PACVS score. A low-level statistically significant correlation was found between the total PSCD and VHS scores. Parents' communicative disease perception and their protection levels affect their vaccination attitudes and vaccine hesitancy. Sociodemographic characteristics, vaccine knowledge and the sources from which they obtain information have both positive and negative relationships on vaccine attitude and vaccine hesitancy. In order to prevent the increasing vaccine refusal in the society, it is recommended that health professionals inform parents through individualized trainings on immunization.

PMID 43015717
Read full article →
PubMedRevista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo2026-11-12

Comparative safety of the 20-valent and the 13-valent pneumococcal vaccines in infants and toddlers: a systematic review and meta-analysis of randomized trials.

Ubaldo Helena Beckhäuser HB, Braga Maria Clara Abreu Vianna MCAV, Silva Elisama da Costa EDC, Lima Lenita de Melo LM

This systematic review and meta-analysis aimed to compare the safety of the 20-valent pneumococcal conjugate vaccine versus the 13-valent pneumococcal vaccine in healthy infants and toddlers. We searched PubMed, Scopus, Embase, and Cochrane on January 20, 2026, for randomized controlled trials comparing the 20-valent pneumococcal conjugate vaccine with the 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers (0-3 years). We computed risk ratios with 95% confidence intervals for all outcomes, using a random-effects model. Heterogeneity was assessed using I2 statistics. Five randomized clinical trials were included, comprising 5,604 patients, of whom 3,059 received the 20-valent pneumococcal conjugate vaccine. There were no significant differences between the 20-valent pneumococcal conjugate vaccine and the 13-valent pneumococcal conjugate vaccine in adverse event incidence after doses 1-3 (risk ratio 1.00; 95%CI 0.92-1.10; p=0.952; I2=0%), or after dose 4 (risk ratio 0.90; 95%CI 0.76-1.07; p=0.238; I2=36%). Similarly, no significant differences were observed in serious adverse events, fever, irritability, and injection site pain. The 20-valent pneumococcal conjugate vaccine was associated with a higher incidence of decreased appetite after doses 2 (risk ratio 1.13, 95%CI 1.02-1.24; p=0.019) and 3 (risk ratio 1.34, 95%CI 1.14-1.58; p<0.001). In contrast, a significantly lower risk of local redness was observed with the 20-valent pneumococcal conjugate vaccine after dose 2 (risk ratio 0.93; 95%CI 0.86-0.99; p=0.034). The 20-valent pneumococcal conjugate vaccine demonstrated a safety profile largely comparable to the 13-valent pneumococcal conjugate vaccine, supporting its use in routine pediatric immunization programs.

PMID 43017995
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about measles vaccine (live-attenuated)